CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock Public Offering	Common Stock At The Market Offering	Common Stock	Additional Paid-in Capital Public Offering	Additional Paid-in Capital At The Market Offering	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Public Offering	At The Market Offering	Total
Balance at beginning of period at Dec. 31, 2020						$ 542,286	$ (94)	$ (504,542)			$ 37,650
Balance at beginning of period (in shares) at Dec. 31, 2020			45,109,314
Increase (Decrease) in Stockholders' Equity
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units						(2,579)					(2,579)
Issuance of common stock in connection with exercise of stock options and warrants and vesting of restricted stock units (in shares)			666,144
Issuance of common stock, net of offering costs				$ 103,348					$ 103,348
Issuance of common stock, net of offering costs (in shares)	6,306,271
Unrealized gain / loss on marketable securities							(35)				(35)
Foreign currency translation adjustment							(11)				(11)
Stock-based compensation expense						2,675					2,675
Net loss								(28,754)			(28,754)
Balance at end of period at Mar. 31, 2021						645,730	(140)	(533,296)			112,294
Balance at end of period (in shares) at Mar. 31, 2021			52,081,729
Balance at beginning of period at Dec. 31, 2020						542,286	(94)	(504,542)			37,650
Balance at beginning of period (in shares) at Dec. 31, 2020			45,109,314
Increase (Decrease) in Stockholders' Equity
Net loss											(46,915)
Balance at end of period at Jun. 30, 2021			$ 1			785,455	(184)	(551,457)			233,815
Balance at end of period (in shares) at Jun. 30, 2021			61,204,987
Balance at beginning of period at Mar. 31, 2021						645,730	(140)	(533,296)			112,294
Balance at beginning of period (in shares) at Mar. 31, 2021			52,081,729
Increase (Decrease) in Stockholders' Equity
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units						1,041					1,041
Issuance of common stock in connection with exercise of stock options and warrants and vesting of restricted stock units (in shares)			1,024,666
Issuance of common stock, net of offering costs	$ 1			$ 134,851					$ 134,852
Issuance of common stock, net of offering costs (in shares)	8,098,592
Unrealized gain / loss on marketable securities							25				25
Foreign currency translation adjustment							(69)				(69)
Stock-based compensation expense						3,833					3,833
Net loss								(18,161)			(18,161)
Balance at end of period at Jun. 30, 2021			$ 1			785,455	(184)	(551,457)			233,815
Balance at end of period (in shares) at Jun. 30, 2021			61,204,987
Balance at beginning of period at Dec. 31, 2021			$ 1			792,971	(224)	(595,407)			$ 197,341
Balance at beginning of period (in shares) at Dec. 31, 2021			61,228,446								61,228,446
Increase (Decrease) in Stockholders' Equity
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units						49					$ 49
Issuance of common stock in connection with exercise of stock options and warrants and vesting of restricted stock units (in shares)			509,037
Unrealized gain / loss on marketable securities							(748)				(748)
Stock-based compensation expense						2,346					2,346
Net loss								(18,789)			(18,789)
Balance at end of period at Mar. 31, 2022			$ 1			795,366	(972)	(614,196)			180,199
Balance at end of period (in shares) at Mar. 31, 2022			61,737,483
Balance at beginning of period at Dec. 31, 2021			$ 1			792,971	(224)	(595,407)			$ 197,341
Balance at beginning of period (in shares) at Dec. 31, 2021			61,228,446								61,228,446
Increase (Decrease) in Stockholders' Equity
Net loss											$ (39,321)
Balance at end of period at Jun. 30, 2022			$ 1			871,805	(1,326)	(634,728)			$ 235,752
Balance at end of period (in shares) at Jun. 30, 2022			66,667,580								66,667,580
Balance at beginning of period at Mar. 31, 2022			$ 1			795,366	(972)	(614,196)			$ 180,199
Balance at beginning of period (in shares) at Mar. 31, 2022			61,737,483
Increase (Decrease) in Stockholders' Equity
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units						88					88
Issuance of common stock in connection with exercise of stock options and warrants and vesting of restricted stock units (in shares)			91,388
Issuance of common stock, net of offering costs					$ 72,659					$ 72,659
Issuance of common stock, net of offering costs (in shares)		4,838,709
Unrealized gain / loss on marketable securities							(354)				(354)
Stock-based compensation expense						3,692					3,692
Net loss								(20,532)			(20,532)
Balance at end of period at Jun. 30, 2022			$ 1			$ 871,805	$ (1,326)	$ (634,728)			$ 235,752
Balance at end of period (in shares) at Jun. 30, 2022			66,667,580								66,667,580